CRISM Therapeutics Corporation
AMMCF
$6.77
$6.573,309.57%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Net Income | 0.00% | 95.43% | 0.00% | -768.64% | 0.00% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 0.00% | -103.09% | 0.00% | 702.89% | -36.38% |
| Change in Net Operating Assets | -- | -- | -- | -- | -- |
| Cash from Operations | 0.00% | 69.89% | 0.00% | 4.91% | -16.31% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | 0.00% | -200.00% | 0.00% | -- | -- |
| Other Investing Activities | 0.00% | 3,693.10% | 0.00% | 14.02% | -- |
| Cash from Investing | 0.00% | -97.26% | 0.00% | 6,779.76% | -460.99% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | 0.00% | 92.65% | 0.00% | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 0.00% | 92.65% | 0.00% | -2,450.96% | -- |
| Foreign Exchange rate Adjustments | 0.00% | 4.35% | 0.00% | -- | -- |
| Miscellaneous Cash Flow Adjustments | 0.00% | -- | -- | -- | -- |
| Net Change in Cash | 0.00% | -192.94% | 0.00% | 271.88% | 15.48% |
